Learn more about ELZONRIS View in browser   Dear decision maker, ELZONRIS™ (tagraxofusp-erzs) Injection for Intravenous (IV) Use is now approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a deadly hematologic cancer.1,2 ELZONRIS Injection for IV Use demonstrated durable efficacy in an open-label, multicenter clinical study (N=44).1,3 Efficacy in treatment-naïve patients (N=29)3   72% CR/CRc rate* 90% ORR 45% bridged to stem cell transplantation   *CRc = clinical complete response; defined as complete response with residual skin abnormality not indicative of active disease.1 CR = complete response; ORR = overall response rate. Median duration of CR/CRc has not yet been reached in treatment-naïve patients (range, 1.3-32.2+ months).3 Median overall survival has not yet been reached; median follow-up 23.0 months (range, 0.2-41.0+ months).3 In the pivotal cohort, treatment-naïve patients (N=13) achieved a 54% CR/CRc rate, 77% ORR, and 46% bridged to stem cell transplantation.1,3 ELZONRIS Injection for IV Use was evaluated in treatment-naïve and previously-treated patients with BPDCN in an open-label, multicenter clinical study (N=44). The pivotal cohort consisted of 13 treatment-naïve patients.1,3 VISIT ELZONRIS.COM/HCP FOR MORE INFORMATION. Medication and coding information ELZONRIS Injection for IV Use is a preservative-free, sterile, clear, colorless, 1,000 mcg in 1 mL solution supplied in a single-dose glass vial. Each carton contains one vial. HCPCS Level II codes: J3490, J3590, or J9999; C9399 Revenue code: 0636 CPT codes: 96413 or 96409 NDC: 72187-0401-1 or 72187-0401-01 ICD-10: C86.4 For more information or questions about financial considerations, please email payer@stemline.com. For clinical questions about ELZONRIS, please email StemlineUS@druginfo.com. INDICATION • ELZONRIS is a CD123-directed cytotoxin for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older IMPORTANT SAFETY INFORMATION Boxed WARNING: CAPILLARY LEAK SYNDROME • Capillary Leak Syndrome (CLS), which may be life-threatening or fatal, can occur in patients receiving ELZONRIS. Monitor for signs and symptoms of CLS and take actions as recommended WARNINGS AND PRECAUTIONS Capillary Leak Syndrome • ELZONRIS can cause capillary leak syndrome (CLS), which may be life-threatening or fatal if not properly managed. The overall incidence of CLS in clinical trials was 55% in patients receiving ELZONRIS, including 46% in Grades 1 or 2, 6% in Grade 3, 1% in Grade 4, and 2 fatal events. Common signs and symptoms (incidence ≥ 20%) associated with CLS that were reported during treatment with ELZONRIS include hypoalbuminemia, edema, weight gain, and hypotension • Before initiating therapy with ELZONRIS, ensure that the patient has adequate cardiac function and serum albumin is ≥ 3.2 g/dL • During treatment with ELZONRIS, ensure that serum albumin levels are ≥ 3.5 g/dL and have not been reduced by ≥ 0.5 g/dL from the albumin value measured prior to dosing initiation of the current cycle. Monitor serum albumin levels prior to the initiation of each dose or more often as indicated clinically thereafter. Additionally, assess patients for other signs or symptoms of CLS, including weight gain, new onset or worsening edema including pulmonary edema, hypotension, or hemodynamic instability • Counsel patients to seek immediate medical attention should signs or symptoms of CLS occur at any time Hypersensivity Reactions • ELZONRIS can cause severe hypersensitivity reactions. Grade 3 or higher events were reported in 10% of patients in clinical trials. Monitor patients for hypersensitivity reactions during treatment with ELZONRIS. Interrupt ELZONRIS infusion and provide supportive care as needed if a hypersensitivity reaction should occur. If the reaction is severe, discontinue ELZONRIS permanently Hepatotoxicity • Elevations in liver enzymes can occur with ELZONRIS. Grade 3 or higher elevations in liver enzymes occurred in approximately 40% of patients in clinical trials • Monitor alanine aminotransferase (ALT) and aspartate aminotransferase (AST) prior to each infusion with ELZONRIS. Temporarily withhold ELZONRIS if the transaminases rise to greater than 5 times the upper limit of normal (ULN) and resume treatment upon normalization or when resolved ADVERSE REACTIONS: The most common adverse reactions in the clinical trials (incidence ≥ 30%) are capillary leak syndrome, nausea, fatigue, peripheral edema, pyrexia, and weight increase. The most common laboratory abnormalities (incidence ≥ 50%) are decreases in albumin, platelets, hemoglobin, calcium, sodium, and increases in glucose, ALT, and AST. Please see full Prescribing Information, including Boxed WARNING. To report SUSPECTED ADVERSE REACTIONS, contact Stemline Therapeutics, Inc. at 1-877-332-7961 or contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. References: 1. ELZONRIS [prescribing information]. New York, NY, US: Stemline Therapeutics, Inc.; December 2018. 2. Pagano L, Valentini CG, Grammatico S, Pulsoni A. Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches. Br J Haematol. 2016;174(2):188-202. 3. Data on file. Stemline Therapeutics, Inc. Copyright 2019 - Stemline Therapeutics, Inc. 750 Lexington Avenue, New York, NY 10022 All rights reserved.  1/2019  US-ELZ-1800020 If you do not wish to receive emails from Stemline Therapeutics, Inc., click here.       Elzonris.com Contact Us Legal Statement Privacy Notice